Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28212060

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2017 Mar 16
First author
Bellmunt J

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Urol. 2017 May;14(5):261. doi: 10.1038/nrurol.2017.38.
    note
    Source null
    related pmid
    28266514
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2017 Mar 20;14(4):197. doi: 10.1038/nrclinonc.2017.38.
    note
    Source null
    related pmid
    28316332
    relationship
    Comment in
  3. citation
    Urology. 2017 Aug;106:1-2. doi: 10.1016/j.urology.2017.04.001.
    note
    Source null
    related pmid
    28454987
    relationship
    Comment in
  4. citation
    N Engl J Med. 2017 Jun 8;376(23):2302. doi: 10.1056/NEJMc1704612.
    note
    Source null
    related pmid
    28591524
    relationship
    Comment in
  5. citation
    N Engl J Med. 2017 Jun 8;376(23):2303-2304. doi: 10.1056/NEJMc1704612.
    note
    Source null
    related pmid
    28591525
    relationship
    Comment in
  6. citation
    N Engl J Med. ;376(23):2302-3. doi: 10.1056/NEJMc1704612.
    note
    Source null
    related pmid
    28594151
    relationship
    Comment in

Authors and identifiers

  1. name
    Bellmunt J
    type
    Author
  2. name
    de Wit R
    type
    Author
  3. name
    Vaughn DJ
    type
    Author
  4. name
    Fradet Y
    type
    Author
  5. name
    Lee JL
    type
    Author
  6. name
    Fong L
    type
    Author
  7. name
    Vogelzang NJ
    type
    Author
  8. name
    Climent MA
    type
    Author
  9. name
    Petrylak DP
    type
    Author
  10. name
    Choueiri TK
    type
    Author
  11. name
    Necchi A
    type
    Author
  12. name
    Gerritsen W
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Bellmunt J
    type
    Author
  2. name
    de Wit R
    type
    Author
  3. name
    Vaughn DJ
    type
    Author
  4. name
    Fradet Y
    type
    Author
  5. name
    Lee JL
    type
    Author
  6. name
    Fong L
    type
    Author
  7. name
    Vogelzang NJ
    type
    Author
  8. name
    Climent MA
    type
    Author
  9. name
    Petrylak DP
    type
    Author
  10. name
    Choueiri TK
    type
    Author
  11. name
    Necchi A
    type
    Author
  12. name
    Gerritsen W
    type
    Author
bibliography ids
  1. nci-bib-956bb593edf9c4e31d981263
book metadata
content sha256
7c5db45570755e69dc8031c8dcec988229a75ffa5de4fdb5a99c47d0802cbc04
document type
citation
dois
  1. 10.1056/NEJMoa1613683
electronic publication date
display
2017 Feb 17
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28212060
immutable id
pubmed:28212060@7c5db45570755e69dc8031c8dcec988229a75ffa5de4fdb5a99c47d0802cbc04
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
11
name
The New England journal of medicine
nlm unique id
0255562
pages
1015-1026
volume
376
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Urol. 2017 May;14(5):261. doi: 10.1038/nrurol.2017.38.
    note
    Source null
    related pmid
    28266514
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2017 Mar 20;14(4):197. doi: 10.1038/nrclinonc.2017.38.
    note
    Source null
    related pmid
    28316332
    relationship
    Comment in
  3. citation
    Urology. 2017 Aug;106:1-2. doi: 10.1016/j.urology.2017.04.001.
    note
    Source null
    related pmid
    28454987
    relationship
    Comment in
  4. citation
    N Engl J Med. 2017 Jun 8;376(23):2302. doi: 10.1056/NEJMc1704612.
    note
    Source null
    related pmid
    28591524
    relationship
    Comment in
  5. citation
    N Engl J Med. 2017 Jun 8;376(23):2303-2304. doi: 10.1056/NEJMc1704612.
    note
    Source null
    related pmid
    28591525
    relationship
    Comment in
  6. citation
    N Engl J Med. ;376(23):2302-3. doi: 10.1056/NEJMc1704612.
    note
    Source null
    related pmid
    28594151
    relationship
    Comment in
outcomes validated
false
pmid
28212060
provenance
batch id
7a1288ac8bb5f9826304
provider
NCBI PubMed ESummary
record sha256
d510ea5b2f76cefb76a58a1be6f7b4a08ca495eff1871b6f018c19d2158aedd2
response sha256
0e879bec8c19d1cfda5629dca8745b04155d18cf54361825d4c070aebad2984d
retrieved at
2026-09-09T23:47:23.138359+00:00
publication date
display
2017 Mar 16
precision
day
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28212060/
title
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Preserved source evidence · Not medical advice